Abstract
Rationale
The muscarinic cholinergic antagonist scopolamine has received an attention due to its unique antidepressant effects. However, the considerable adverse effects on nervous system limit the use of scopolamine as a psychiatric drug.
Objective
In order to overcome the limitations and increase the therapeutic effects of scopolamine, we decided to examine the effects of joint administration of sub-effective dose of scopolamine and the sub-effective dose of a nitric oxide (NO) precursor l-Arginine or a non-selective nitric oxide synthase (NOS) inhibitor l-NAME on depression- and anxiety-related behaviors in male NMRI mice.
Methods
To this aim, animal behavior was assessed in the forced swim test (FST) and hole-board apparatus.
Results
Scopolamine (0.05 mg/kg) significantly decreased immobility time in the FST, suggesting an antidepressant-like effect. Moreover, l-Arginine (50 mg/kg) produced an antidepressant-like response in the FST and decreased head-dip counts in the hole-board apparatus, indicating an anxiety-like effect. The same doses of scopolamine and l-Arginine decreased the locomotor activity in mice. Joint administration of sub-effective dose of scopolamine (0.01 mg/kg) with a low dose of l-Arginine (25 mg/kg) or l-NAME (1 mg/kg) induced a profound antidepressant-like effect in the FST. These drug combinations did not influence on anxiety-related behaviors. Meanwhile, l-NAME alone did not alter the performance of mice in the FST and hole-board. Isobolographic analysis revealed an additive effect for scopolamine and l-Arginine or l-NAME.
Conclusion
Data suggests that NO agents could positively impact the therapeutic profile of scopolamine, because they might be useful for inducing antidepressant-like effect associated to scopolamine.
Similar content being viewed by others
References
Ali AK, Banks WA, Kumar VB, Shah GN, Lynch JL, Farr SA, Fleegal-DeMotta MA, Morley JE (2009) Nitric oxide activity and isoenzyme expression in the senescence-accelerated mouse p8 model of Alzheimer’s disease: effects of anti-amyloid antibody and antisense treatments. J Gerontol A Biol Sci Med Sci 64:1025–1030. https://doi.org/10.1093/gerona/glp074
Alijanpour S, Khakpai F, Ebrahimi-Ghiri M, Zarrindast M-R (2019) Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomed Pharmacother 109:589–594. https://doi.org/10.1016/j.biopha.2018.10.033
Aracri P, Consonni S, Morini R, Perrella M, Rodighiero S, Amadeo A, Becchetti A (2010) Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex. Cereb Cortex 20:1539–1555. https://doi.org/10.1093/cercor/bhp214
Baek I-S, Park J-Y, Han P-L (2015) Chronic antidepressant treatment in normal mice induces anxiety and impairs stress-coping ability. Exp Neurobiol 24:156–168. https://doi.org/10.5607/en.2015.24.2.156
Barik J, Wonnacott S (2006) Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol 69:618–628. https://doi.org/10.1124/mol.105.018184
Beiranvand F, Zlabinger C, Orr-Urtreger A, Ristl R, Huck S, Scholze P (2014) Nicotinic acetylcholine receptors control acetylcholine and noradrenaline release in the rodent habenulo-interpeduncular complex. Br J Pharmacol 171:5209–5224. https://doi.org/10.1111/bph.12841
Borda T, Genaro A, Sterin-Borda L, Cremaschi G (1998) Involvement of endogenous nitric oxide signalling system in brain muscarinic acetylcholine receptor activation. J Neural Transm 105:193–204. https://doi.org/10.1007/s007020050048
Bortz DM, Mikkelsen JD, Bruno JP (2013) Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience 255:55–67. https://doi.org/10.1016/j.neuroscience.2013.09.047
Bugajski AJ, Gadek-Michalska A, Bugajski J (2006) The involvement of nitric oxide and prostaglandins in the cholinergic stimulation of hypothalamie-pituitary-adrenal response during crowding stress. J Physiol Pharmacol 57:463–477
Calixto AV, Duarte FS, Duzzioni M, Nascimento Häckl LP, Faria MS, de Lima TCM (2010) Role of ventral hippocampal nitric oxide/cGMP pathway in anxiety-related behaviors in rats submitted to the elevated T-maze. Behav Brain Res 207:112–117. https://doi.org/10.1016/j.bbr.2009.09.037
da Silva GD, Matteussi AS, dos Santos AR et al (2000) Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 11:3699–3702
de Oliveira RM, Aparecida Del Bel E, Mamede-Rosa ML et al (2000) Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. Neurosci Lett 289:123–126
Del Bel EA, Guimaraes FS, Bermudez-Echeverry M et al (2005) Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25:371–392
Deshpande SR, Satyanarayana K, Rao MNA, Pai KV (2012) Nitric oxide modulators: an emerging class of medicinal agents. Indian J Pharm Sci 74:487–497. https://doi.org/10.4103/0250-474X.110572
Dhir A, Kulkarni SK (2011) Nitric oxide and major depression. Nitric Oxide - Biol Chem 24:125–131. https://doi.org/10.1016/j.niox.2011.02.002
Dougherty JJ, Nichols RA (2009) Cross-regulation between colocalized nicotinic acetylcholine and 5-HT3 serotonin receptors on presynaptic nerve terminals. Acta Pharmacol Sin 30:788–794. https://doi.org/10.1038/aps.2009.62
Dulawa SC, Janowsky DS (2018) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry 24:694–709. https://doi.org/10.1038/s41380-018-0219-x
Ergun Y, Ergun UGO (2007) Prevention of pro-depressant effect of L-arginine in the forced swim test by NG-nitro-L-arginine and [1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one]. Eur J Pharmacol 554:150–154. https://doi.org/10.1016/j.ejphar.2006.09.067
Forestiero D, Manfrim CM, Guimaraes FS, de Oliveira RMW (2006) Anxiolytic-like effects induced by nitric oxide synthase inhibitors microinjected into the medial amygdala of rats. Psychopharmacology 184:166–172. https://doi.org/10.1007/s00213-005-0270-6
Furey ML, Khanna A, Hoffman EM, Drevets WC (2010) Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 35:2479–2488. https://doi.org/10.1038/npp.2010.131
Garduno J, Galindo-Charles L, Jimenez-Rodriguez J, Galarraga E, Tapia D, Mihailescu S, Hernandez-Lopez S (2012) Presynaptic alpha4beta2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. J Neurosci 32:15148–15157. https://doi.org/10.1523/JNEUROSCI.0941-12.2012
Garthwaite J, Garthwaite G, Palmer RM, Moncada S (1989) NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 172:413–416
Ghasemi M, Claunch J, Niu K (2019) Pathologic role of nitrergic neurotransmission in mood disorders. Prog Neurobiol 173:54–87. https://doi.org/10.1016/j.pneurobio.2018.06.002
Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, Duman RS (2018) Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry 83:29–37. https://doi.org/10.1016/j.biopsych.2017.06.017
Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5:545–552. https://doi.org/10.1038/nrn1429
Guimaraes FS, Beijamini V, Moreira FA et al (2005) Role of nitric oxide in brain regions related to defensive reactions. Neurosci Biobehav Rev 29:1313–1322. https://doi.org/10.1016/j.neubiorev.2005.03.026
Heiberg IL, Wegener G, Rosenberg R (2002) Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134:479–484
Inan SY, Yalcin I, Aksu F (2004) Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 77:457–464. https://doi.org/10.1016/j.pbb.2003.12.024
Iniguez SD, Vialou V, Warren BL, Cao JL, Alcantara LF, Davis LC, Manojlovic Z, Neve RL, Russo SJ, Han MH, Nestler EJ, Bolanos-Guzman CA (2010) Extracellular signal-regulated kinase-2 within the ventral tegmental area regulates responses to stress. J Neurosci 30:7652–7663. https://doi.org/10.1523/JNEUROSCI.0951-10.2010
Kalouda T, Pitsikas N (2015) The nitric oxide donor molsidomine induces anxiolytic-like behaviour in two different rat models of anxiety. Pharmacol Biochem Behav 138:111–116. https://doi.org/10.1016/j.pbb.2015.09.004
Karolewicz B, Paul IA, Antkiewicz-Michaluk L (2001) Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 53:587–596
Kenny PJ, File SE, Neal MJ (2000) Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 75:2409–2414
Khakpoor M, Nasehi M, Vahdati A, Hoseyni SE, Zarrindast MR (2016) Additive effect of BLA GABAAreceptor mechanism and (+)-MK-801 on memory retention deficit, an isobologram analysis. Pharmacol Biochem Behav 143:57–64. https://doi.org/10.1016/j.pbb.2016.02.001
Kim J, Isokawa M, Ledent C, Alger BE (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 22:10182–10191
Klinkenberg I, Blokland A (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 34:1307–1350. https://doi.org/10.1016/j.neubiorev.2010.04.001
Kopf SR, Benton RS, Kalfin R, Giovannini MG, Pepeu G (2001) NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res 894:141–144
Kruk-Slomka M, Michalak A, Biala G (2015) Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system. Behav Brain Res 284:24–36. https://doi.org/10.1016/j.bbr.2015.01.051
Kurt M, Bilge SS, Aksoz E, Kukula O, Celik S, Kesim Y (2004) Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol 56:353–357
Li DP, Pan YZ, Pan HL (2001) Acetylcholine attenuates synaptic GABA release to supraoptic neurons through presynaptic nicotinic receptors. Brain Res 920:151–158
Lin Y-G, Chen P-H, Chang F-Y, Wu LT, Liao KY, Wu TC (2011) Delirium due to scopolamine patch in a 4-year-old boy. J Formos Med Assoc 110:208–211. https://doi.org/10.1016/S0929-6646(11)60031-4
Machawal L, Kumar A (2014) Possible involvement of nitric oxide mechanism in the neuroprotective effect of rutin against immobilization stress induced anxiety like behaviour, oxidative damage in mice. Pharmacol Rep 66:15–21. https://doi.org/10.1016/j.pharep.2013.08.001
Maggi L, Sher E, Cherubini E (2001) Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol 536:89–100
Mancinelli A, Borsini F, d’Aranno V et al (1988) Cholinergic drug effects on antidepressant-induced behaviour in the forced swimming test. Eur J Pharmacol 158:199–205
Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244
Morato GS, Ortiga RM, Ferreira VMM (2004) Involvement of nitric oxide-dependent pathways of dorsolateral periaqueductal gray in the effects of ethanol in rats submitted to the elevated plus-maze test. Behav Brain Res 153:341–349. https://doi.org/10.1016/j.bbr.2003.12.010
Ostadhadi S, Norouzi-Javidan A, Nikoui V, Zolfaghari S, Moradi A, Dehpour AR (2018) Nitric oxide involvement in additive antidepressant-like effect of agmatine and lithium in mice forced swim test. Psychiatry Res 266:262–268. https://doi.org/10.1016/j.psychres.2018.03.010
Palucha-Poniewiera A, Podkowa K, Lenda T, Pilc A (2017) The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Prog Neuro-Psychopharmacol Biol Psychiatry 79:155–161. https://doi.org/10.1016/j.pnpbp.2017.06.022
Petryshen TL, Lewis MC, Dennehy KA, Garza JC, Fava M (2016) Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice. Neurosci Lett 620:70–73. https://doi.org/10.1016/j.neulet.2016.03.051
Pistell PJ, Daffin LWJ, Nelson CM et al (2007) Combined administration of subthreshold doses of the nitric oxide inhibitor, nitro-L-arginine, and muscarinic receptor antagonist, scopolamine, impairs complex maze learning in rats. Behav Pharmacol 18:801–805. https://doi.org/10.1097/FBP.0b013e3282f18d2f
Podkowa K, Podkowa A, Sałat K, Lenda T, Pilc A, Pałucha-Poniewiera A (2016) Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology 111:169–179. https://doi.org/10.1016/j.neuropharm.2016.08.031
Podkowa K, Pilc A, Podkowa A, Sałat K, Marciniak M, Pałucha-Poniewiera A (2018) The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. Neuropharmacology 141:214–222. https://doi.org/10.1016/j.neuropharm.2018.08.022
Reno LAC, Zago W, Markus RP (2004) Release of [(3)H]-L-glutamate by stimulation of nicotinic acetylcholine receptors in rat cerebellar slices. Neuroscience 124:647–653. https://doi.org/10.1016/j.neuroscience.2003.12.023
Roohbakhsh A, Moghaddam AH, Massoudi R, Zarrindast M-R (2007) Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 34:223–229. https://doi.org/10.1111/j.1440-1681.2007.04576.x
Schwartz RD, Lehmann J, Kellar KJ (1984) Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain. J Neurochem 42:1495–1498
Sestakova N, Puzserova A, Kluknavsky M, Bernatova I (2013) Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol 6:126–135. https://doi.org/10.2478/intox-2013-0020
Sharples CG, Kaiser S, Soliakov L et al (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783–2791
Singh P, Singh TG (2015) Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. Indian J Pharmacol 47:388–393. https://doi.org/10.4103/0253-7613.161260
Small KM, Nunes E, Hughley S, Addy NA (2016) Ventral tegmental area muscarinic receptors modulate depression and anxiety-related behaviors in rats. Neurosci Lett 616:80–85. https://doi.org/10.1016/j.neulet.2016.01.057
Spiacci AJ, Kanamaru F, Guimaraes FS, Oliveira RMW (2008) Nitric oxide-mediated anxiolytic-like and antidepressant-like effects in animal models of anxiety and depression. Pharmacol Biochem Behav 88:247–255. https://doi.org/10.1016/j.pbb.2007.08.008
Sugaya K, McKinney M (1994) Nitric oxide synthase gene expression in cholinergic neurons in the rat brain examined by combined immunocytochemistry and in situ hybridization histochemistry. Brain Res Mol Brain Res 23:111–125
Takeda H, Tsuji M, Matsumiya T (1998) Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350:21–29
Udayabanu M, Kumaran D, Nair RU, Srinivas P, Bhagat N, Aneja R, Katyal A (2008) Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res 1230:138–149. https://doi.org/10.1016/j.brainres.2008.06.081
Utkan T, Gocmez SS, Regunathan S, Aricioglu F (2012) Agmatine, a metabolite of L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav 102:578–584. https://doi.org/10.1016/j.pbb.2012.07.003
Voleti B, Navarria A, Liu R-J, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS (2013) Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74:742–749. https://doi.org/10.1016/j.biopsych.2013.04.025
Wegener G, Volke V (2010) Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals 3:273–299. https://doi.org/10.3390/ph3010273
Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, Duman RS (2016) GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest 126:2482–2494. https://doi.org/10.1172/JCI85033
Zarrindast M-R, Nasehi M, Khansari M, Bananej M (2011a) Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. Neurosci Lett 489:38–42. https://doi.org/10.1016/j.neulet.2010.11.062
Zarrindast MR, Nasehi M, Piri M, Heidari N (2011b) Effects of cholinergic system of dorsal hippocampus of rats on MK-801 induced anxiolytic-like behavior. Neurosci Lett 505:65–70. https://doi.org/10.1016/j.neulet.2011.08.009
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 379 kb)
Rights and permissions
About this article
Cite this article
Nasehi, M., Mohammadi-Mahdiabadi-Hasani, MH., Ebrahimi-Ghiri, M. et al. Additive interaction between scopolamine and nitric oxide agents on immobility in the forced swim test but not exploratory activity in the hole-board. Psychopharmacology 236, 3353–3362 (2019). https://doi.org/10.1007/s00213-019-05294-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-019-05294-0